Stephen A Sherwin - Net Worth and Insider Trading

Stephen A Sherwin Net Worth

The estimated net worth of Stephen A Sherwin is at least $6 Million dollars as of 2024-11-10. Stephen A Sherwin is the Director of Neurocrine Biosciences Inc and owns about 26,504 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $3 Million. Stephen A Sherwin is the Director of Biogen Inc and owns about 15,438 shares of Biogen Inc (BIIB) stock worth over $3 Million. Stephen A Sherwin is also the Director of Fresh Tracks Therapeutics Inc and owns about 2 shares of Fresh Tracks Therapeutics Inc (FRTX) stock worth over $1. Details can be seen in Stephen A Sherwin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stephen A Sherwin has not made any transactions after 2024-05-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Stephen A Sherwin

Stephen A Sherwin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Stephen A Sherwin owns 12 companies in total, including Biogen Inc (BIIB) , Neurocrine Biosciences Inc (NBIX) , and Neon Therapeutics Inc (NTGN) among others .

Click here to see the complete history of Stephen A Sherwin’s form 4 insider trades.

Insider Ownership Summary of Stephen A Sherwin

Ticker	Comapny	Transaction Date	Type of Owner
BIIB	Biogen Inc	2020-03-11	director
NBIX	Neurocrine Biosciences Inc	2024-05-29	director
NTGN	Neon Therapeutics Inc	2020-05-06	director
		2020-05-05	director
		2003-07-28	director
		2013-03-05	director
		2013-05-23	director
		2009-10-14	director
		2018-06-06	director
		2021-12-02	director
		2022-09-16	director
		2022-09-16	director

Stephen A Sherwin Latest Holdings Summary

Stephen A Sherwin currently owns a total of 3 stocks. Among these stocks, Stephen A Sherwin owns 26,504 shares of Neurocrine Biosciences Inc (NBIX) as of May 29, 2024, with a value of $3 Million and a weighting of 55.51%. Stephen A Sherwin owns 15,438 shares of Biogen Inc (BIIB) as of March 11, 2020, with a value of $3 Million and a weighting of 44.49%. Stephen A Sherwin also owns 2 shares of Fresh Tracks Therapeutics Inc (FRTX) as of May 23, 2013, with a value of $1 and a weighting of 0%.

Latest Holdings of Stephen A Sherwin

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
NBIX	Neurocrine Biosciences Inc	2024-05-29	26,504	125.74	3,332,613
BIIB	Biogen Inc	2020-03-11	15,438	173.02	2,671,083
FRTX	Fresh Tracks Therapeutics Inc	2013-05-23	2	0.74	1

Holding Weightings of Stephen A Sherwin

Stephen A Sherwin Form 4 Trading Tracker

According to the SEC Form 4 filings, Stephen A Sherwin has made a total of 4 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Neurocrine Biosciences Inc is the sale of 40,000 shares on May 29, 2024, which brought Stephen A Sherwin around $5 Million.

According to the SEC Form 4 filings, Stephen A Sherwin has made a total of 1 transactions in Biogen Inc (BIIB) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Biogen Inc is the sale of 2,434 shares on March 11, 2020, which brought Stephen A Sherwin around $718,566.

According to the SEC Form 4 filings, Stephen A Sherwin has made a total of 0 transactions in Fresh Tracks Therapeutics Inc (FRTX) over the past 5 years. The most-recent trade in Fresh Tracks Therapeutics Inc is the acquisition of 2 shares on May 23, 2013, which cost Stephen A Sherwin around $70.

Insider Trading History of Stephen A Sherwin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Stephen A Sherwin Trading Performance

GuruFocus tracks the stock performance after each of Stephen A Sherwin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stephen A Sherwin is -62.29%. GuruFocus also compares Stephen A Sherwin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stephen A Sherwin within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Stephen A Sherwin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Stephen A Sherwin

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-16.76
Relative Return to S&P 500(%)	-13.24

Stephen A Sherwin Ownership Network

Ownership Network List of Stephen A Sherwin

No Data

Ownership Network Relation of Stephen A Sherwin

Stephen A Sherwin Owned Company Details

What does Biogen Inc do?

Who are the key executives at Biogen Inc?

Stephen A Sherwin is the director of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , Head of Research Jane Grogan , and EVP & Human Resources Ginger Gregory .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 2,569 shares made by Priya Singhal , and a net purchase of 455 shares made by Eric K Rowinsky .

In summary, during the past 3 months, insiders sold 431 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 431 shares. During the past 18 months, 2,569 shares of Biogen Inc (BIIB) were sold and 455 shares were bought by its insiders, resulting in a net sale of 2,114 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biogen Inc Insider Transactions

No Available Data

What does Neurocrine Biosciences Inc do?

Who are the key executives at Neurocrine Biosciences Inc?

Stephen A Sherwin is the director of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Corp. Affairs Officer David W. Boyer , Chief Regulatory Officer Ingrid Delaet , and Chief Financial Officer Matt Abernethy .

Neurocrine Biosciences Inc (NBIX) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Neurocrine Biosciences Inc (NBIX). Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 32,776 shares made by Ingrid Delaet , a net sale of 58,181 shares made by Darin Lippoldt , and a net sale of 55,568 shares made by Julie Cooke .

In summary, during the past 3 months, insiders sold 51,819 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 51,819 shares. During the past 18 months, 993,959 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 993,959 shares.

Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neurocrine Biosciences Inc Insider Transactions

No Available Data

What does Neon Therapeutics Inc do?

Who are the key executives at Neon Therapeutics Inc?

Stephen A Sherwin is the director of Neon Therapeutics Inc. Other key executives at Neon Therapeutics Inc include President of R&D Richard Gaynor , director & 10 percent owner Robert I Tepper , and Chief Financial Officer Yasir B. Al-wakeel .

Neon Therapeutics Inc (NTGN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Neon Therapeutics Inc (NTGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neon Therapeutics Inc (NTGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Neon Therapeutics Inc (NTGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neon Therapeutics Inc Insider Transactions

No Available Data

What does Aduro Biotech Inc do?

Who are the key executives at Aduro Biotech Inc?

Stephen A Sherwin is the director of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .

Aduro Biotech Inc (ADRO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aduro Biotech Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Stephen A Sherwin is the director of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Stephen A Sherwin is the director of Verastem Inc. Other key executives at Verastem Inc include Chief Operating Officer Dan Paterson , Vice President of Finance Daniel Calkins , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 668 shares made by Daniel Calkins , a net sale of 20,888 shares made by Robert E. Gagnon , and a net sale of 6,617 shares made by Dan Paterson .

In summary, during the past 3 months, insiders sold 2,695 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 2,695 shares. During the past 18 months, 33,122 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 33,122 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does Fresh Tracks Therapeutics Inc do?

Who are the key executives at Fresh Tracks Therapeutics Inc?

Stephen A Sherwin is the director of Fresh Tracks Therapeutics Inc. Other key executives at Fresh Tracks Therapeutics Inc include Chief Medical Officer Monica E. Luchi , director & CHAIRMAN OF THE BOARD Reginald L Hardy , and General Counsel and CCO David R. Mcavoy .

Fresh Tracks Therapeutics Inc (FRTX) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Fresh Tracks Therapeutics Inc (FRTX). Other recent insider transactions involving Fresh Tracks Therapeutics Inc (FRTX) include a net sale of 110 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of Fresh Tracks Therapeutics Inc (FRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 110 shares of Fresh Tracks Therapeutics Inc (FRTX) were sold and 1,086,412 shares were bought by its insiders, resulting in a net purchase of 1,086,302 shares.

Fresh Tracks Therapeutics Inc (FRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fresh Tracks Therapeutics Inc Insider Transactions

No Available Data

What does ANI Pharmaceuticals Inc do?

Who are the key executives at ANI Pharmaceuticals Inc?

Stephen A Sherwin is the director of ANI Pharmaceuticals Inc. Other key executives at ANI Pharmaceuticals Inc include SR. VP & GENERAL COUNSEL & SEC. Meredith Cook , director & HEAD OF R&D & COO-NOVITIUM OPS Muthusamy Shanmugam , and SVP - CORP. DEV. & STRATEGY Chad Gassert .

ANI Pharmaceuticals Inc (ANIP) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in ANI Pharmaceuticals Inc (ANIP). Other recent insider transactions involving ANI Pharmaceuticals Inc (ANIP) include a net sale of 776,190 shares made by Muthusamy Shanmugam , a net sale of 3,000 shares made by Meredith Cook , and a net sale of 200,000 shares made by Chad Gassert .

In summary, during the past 3 months, insiders sold 750 shares of ANI Pharmaceuticals Inc (ANIP) in total and bought 0 shares, with a net sale of 750 shares. During the past 18 months, 1,411,262 shares of ANI Pharmaceuticals Inc (ANIP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,411,262 shares.

ANI Pharmaceuticals Inc (ANIP)'s detailed insider trading history can be found in Insider Trading Tracker table.

ANI Pharmaceuticals Inc Insider Transactions

No Available Data

What does Chinook Therapeutics Inc do?

Who are the key executives at Chinook Therapeutics Inc?

Stephen A Sherwin is the director of Chinook Therapeutics Inc. Other key executives at Chinook Therapeutics Inc include Head of Renal Discovery Andrew James King , director & President & CEO Eric Dobmeier , and director & 10 percent owner Davis Jerel .

Chinook Therapeutics Inc (KDNY) Insider Trades Summary

Over the past 18 months, Stephen A Sherwin made no insider transaction in Chinook Therapeutics Inc (KDNY). Other recent insider transactions involving Chinook Therapeutics Inc (KDNY) include a net sale of 1,168 shares made by Andrew James King , and a net sale of 1,155 shares made by William Mariner Greenman .

In summary, during the past 3 months, insiders sold 0 shares of Chinook Therapeutics Inc (KDNY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,323 shares of Chinook Therapeutics Inc (KDNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,323 shares.

Chinook Therapeutics Inc (KDNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chinook Therapeutics Inc Insider Transactions

No Available Data

What does BioPlus Acquisition Corp do?

Who are the key executives at BioPlus Acquisition Corp?

Stephen A Sherwin is the director of BioPlus Acquisition Corp. Other key executives at BioPlus Acquisition Corp include 10 percent owner Steven C. Fletcher , 10 percent owner Explorer Parent Llc , and 10 percent owner Founder Holdings Llc .

BioPlus Acquisition Corp (BIOS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioPlus Acquisition Corp (BIOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioPlus Acquisition Corp (BIOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioPlus Acquisition Corp (BIOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioPlus Acquisition Corp Insider Transactions

No Available Data

What does Epiphany Technology Acquisition Corp do?

Who are the key executives at Epiphany Technology Acquisition Corp?

Stephen A Sherwin is the director of Epiphany Technology Acquisition Corp. Other key executives at Epiphany Technology Acquisition Corp include director & Co-Chief Executive Officer Ross Haghighat , director & Chairman Coviello Arthur W Jr , and director & Vice Chairman Paul F Deninger .

Epiphany Technology Acquisition Corp (EPHY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epiphany Technology Acquisition Corp (EPHY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epiphany Technology Acquisition Corp (EPHY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epiphany Technology Acquisition Corp (EPHY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epiphany Technology Acquisition Corp Insider Transactions

No Available Data

What does Epiphany Technology Acquisition Corp do?

Who are the key executives at Epiphany Technology Acquisition Corp?

Epiphany Technology Acquisition Corp (EPHYU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epiphany Technology Acquisition Corp (EPHYU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epiphany Technology Acquisition Corp (EPHYU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epiphany Technology Acquisition Corp (EPHYU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epiphany Technology Acquisition Corp Insider Transactions

No Available Data

Stephen A Sherwin Mailing Address

Above is the net worth, insider trading, and ownership report for Stephen A Sherwin. You might contact Stephen A Sherwin via mailing address: C/o Cell Genesys, Inc., 500 Forbes Blvd., South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.